---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-087284"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:46:06.201485+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns appoints new Chief Legal Officer; CFO and General Counsel to depart in planned transitions

## Summary
- Elona Kogan appointed Chief Legal Officer effective July 29; previously CLO at Seer, Inc.
- CFO Mark Vignola to leave by Feb 1, 2025 or upon successor; receives $475k severance plus $500k retention bonus.
- General Counsel Bryan Yoon steps down, becomes COO/Special Counsel until Sep 3, 2024; receives $490,700 severance.
- Search for new CFO underway; Vignola and Yoon remain in transition roles.

## SEC filing metadata
- accession: 0000950170-24-087284
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024087284/0000950170-24-087284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024087284/tern-20240723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-087284
- JSON: https://secwatch.observer/filing/0000950170-24-087284.json
- Plain text: https://secwatch.observer/filing/0000950170-24-087284.txt

## Source-grounded claims
- claim_id: 1b141b8c4c
  claim: Mark Vignola departed as Chief Financial Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: Dr. Vignola’s continued service as Chief Financial Officer for a transition period until the date of his separation from employment (the “Vignola Separation Date”), anticipated to be February 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017024087284/0000950170-24-087284-index.htm
- claim_id: 1cab0a561c
  claim: Bryan Yoon changed role as General Counsel at Terns Pharmaceuticals, Inc..
  evidence_excerpt: Effective upon the execution of the Yoon Separation Agreement, Mr. Yoon has assumed the title of Chief Operating Officer and Special Counsel and has ceased to serve as General Counsel and Secretary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017024087284/0000950170-24-087284-index.htm
- claim_id: 5175d4122f
  claim: Bryan Yoon departed as Chief Operating Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: The Yoon Separation Agreement provides for Mr. Yoon’s continued service as Chief Operating Officer and Special Counsel for a transition period until September 3, 2024 (the “Yoon Separation Date”). Mr. Yoon’s employment will terminate and he will cease to hold any positions with the Company as of the Yoon Separation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017024087284/0000950170-24-087284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.